elranatamab will improve the amount or influence of ergotamine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Check. Elranatamab triggers cytokine release syndrome (CRS) that will suppress exercise of CYP enzymes, causing elevated publicity of CYP substrates.isavuconazonium sulfate will increase the level or impact of ergotam